Go to content
UR Home

Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma

Hau, Peter ; Koch, D. ; Hundsberger, T. ; Marg, E. ; Bauer, B. ; Rudolph, R. ; Rauch, M. ; Brenner, A. ; Rieckmann, P. ; Schuth, J. ; Jauch, T. ; Koch, H. ; Bogdahn, U.


We surveyed neuro-oncologists regarding patients treated with temozolomide for at least 12 cycles or 12 months. Patients receiving first-line temozolomide for a median 13 cycles had a median progression-free survival (PFS) of 14 months. Patients with recurrent disease receiving a median 14 cycles had a median PFS of 15.5 months. A small percentage of patients experienced grade III to IV toxicity. These results suggest that long-term treatment with temozolomide is feasible and well tolerated.

Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons